Evidence map›Paper›PMID 35774851›Full record

ArticleDisease markers2022

Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer.

Qingfang Yue, Yuan Zhang, Jun Bai, Xianglong Duan, Haipeng Wang

Open access · hybridAbstract read
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Identification of mFrontiers in genetics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Qingfang YueDepartment of Medical Oncology, Shaanxi Provincial People's Hospital, Xi'an, 710068 Shaanxi, China.ORCID https://orcid.org/0000-0003-4664-0305
Yuan ZhangDepartment of Medical Oncology, Shaanxi Provincial People's Hospital, Xi'an, 710068 Shaanxi, China.ORCID https://orcid.org/0000-0003-3540-2205
Jun BaiDepartment of Medical Oncology, Shaanxi Provincial People's Hospital, Xi'an, 710068 Shaanxi, China.ORCID https://orcid.org/0000-0003-0359-322X
Xianglong DuanInstitute of Medical Research, Northwestern Polytechnic University, Xi'an, 710072 Shaanxi, China.ORCID https://orcid.org/0000-0002-2717-8656
Haipeng WangDepartment of Medical Oncology, Shaanxi Provincial People's Hospital, Xi'an, 710068 Shaanxi, China.ORCID https://orcid.org/0000-0002-3679-4557
Shanxi Medical University · CNNorthwestern Polytechnical University · CNXizang Minzu University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Noncoding ribonucleic acids (ncRNAs) are involved in various functions in the formation and progression of different tumors. However, the association between N6-methyladenosine-related ncRNAs (m6A-related ncRNAs) and gastric cancer (GC) prognosis remains elusive. As such, this research was aimed at identifying m6A-related ncRNAs (lncRNAs and miRNAs) in GC and developing prognostic models of relevant m6A-related ncRNAs and identifying potential biomarkers regulated by m6A. In this study, the m6A2Target database, Starbase database, and The Cancer Genome Atlas (TCGA) were used to screen m6A-related ncRNAs. And then, we performed integrated bioinformatics analyses to determine prognosis-associated ncRNAs and to develop the m6A-related ncRNA prognostic signature (m6A-NPS) for GC patients. Finally, five m6A-related ncRNAs (including lnc-ARHGAP12, lnc-HYPM-1, lnc-WDR7-11, LINC02266, and lnc-PRIM2-7) were identified to establish m6A-NPS. The predictive power of m6A-NPS was better in the receiver operating characteristic (ROC) curve analysis of the training set (area under the curve (AUC), >0.6). The m6A-NPS could be utilized to classify patients into high- and low-risk cohorts, and the Kaplan-Meier analysis indicated that participants in the high-risk cohort had a poorer prognosis. The entire TCGA dataset substantiated the predictive value of m6A-NPS. Significant differences in TCGA molecular GC subtypes were observed between high- and low-risk cohorts. The ROC curve analysis indicated that m6A-NPS had better predictive power than other clinical characteristics of GC prognosis. Uni- and multivariate regression analyses indicated m6A-NPS as an independent prognostic factor. Furthermore, the m6A status between the low-risk cohort and high-risk cohort was significantly different. Differential genes between them were enriched in multiple tumor-associated signaling pathways. In summary, five m6A-related ncRNA signatures that could forecast the overall survival of patients with GC were identified.

Indexed as

RNA, Long NoncodingStomach NeoplasmsAdaptor Proteins, Signal TransducingAdenosineCohort StudiesHumansPrognosisAdaptor Proteins, Signal TransducingAdenosineRNA, Long NoncodingWDR7 protein, human

Identifiers

PMID35774851
PMCPMC9239763
OpenAlexW4225776271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.